VMI:NYSEValmont Industries, Inc. Analysis
Data as of 2026-05-09 - not real-time
$510.55
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Valmont Industries delivered a Q1 2026 earnings beat, posting revenue growth of 6.2% year‑over‑year to $1.03 billion and an EPS of $5.51 versus the consensus estimate of $4.72. The stock is trading at $510.55, just below the 52‑week high of $528.49 and comfortably above the 20‑, 50‑ and 200‑day moving averages, while the MACD remains bullish and the RSI sits at 67.5, indicating momentum but approaching overbought levels. Volume is trending lower, which could temper short‑term upside despite the strong technical backdrop.
Valuation metrics paint a mixed picture: the trailing P/E of 28.4 is slightly below the industry average of 29.9, and the forward P/E of 20.1 suggests earnings acceleration, yet the DCF‑derived fair value of $127.84 implies the market price is substantially overvalued with only a 3.2% upside potential. The dividend yield is modest at 0.57% with a low payout ratio of 15.6%, supporting sustainability, while a debt‑to‑equity of 55% and a beta of 1.24 signal moderate financial leverage and higher market sensitivity. Overall, the company benefits from solid revenue growth, strong cash generation, and a favorable industry backdrop, but the current premium pricing and elevated volatility warrant a cautious stance.
Valuation metrics paint a mixed picture: the trailing P/E of 28.4 is slightly below the industry average of 29.9, and the forward P/E of 20.1 suggests earnings acceleration, yet the DCF‑derived fair value of $127.84 implies the market price is substantially overvalued with only a 3.2% upside potential. The dividend yield is modest at 0.57% with a low payout ratio of 15.6%, supporting sustainability, while a debt‑to‑equity of 55% and a beta of 1.24 signal moderate financial leverage and higher market sensitivity. Overall, the company benefits from solid revenue growth, strong cash generation, and a favorable industry backdrop, but the current premium pricing and elevated volatility warrant a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent earnings beat and strong revenue growth
- Technical bullishness but RSI near overbought and decreasing volume
- Valuation gap between market price and DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward earnings expansion reflected in a forward P/E of 20.1
- Sustainable dividend with low payout ratio
- Continued demand in infrastructure and agriculture segments
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Stable cash flow and solid ROE (~22%)
- Elevated valuation relative to DCF estimates
- Moderate leverage and higher beta indicating market sensitivity
Key Metrics & Analysis
Financial Health
Revenue Growth6.20%
Profit Margin8.91%
P/E Ratio28.4
ROE22.19%
ROA10.08%
Debt/Equity54.96
P/B Ratio6.1
Op. Cash Flow$494.8M
Free Cash Flow$187.2M
Industry P/E29.9
Technical Analysis
TrendBullish
RSI67.6
Support$394.46
Resistance$528.49
MA 20$474.49
MA 50$439.64
MA 200$414.67
MACDBullish
VolumeDecreasing
Fear & Greed Index90.73
Valuation
Fair Value$127.84
Target Price$527.00
Upside/Downside3.22%
GradeOvervalued
TypeGrowth
Dividend Yield0.57%
Risk Assessment
Beta1.24
Volatility46.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.